<DOC>
	<DOCNO>NCT00430534</DOCNO>
	<brief_summary>To evaluate safety , immune-response efficacy GSK Biologicals ’ EBV vaccine population risk develop infectious mononucleosis . Each subject receive three dos vaccine placebo study period .</brief_summary>
	<brief_title>Evaluation Safety , Immune-Response Efficacy GSK Biologicals ’ EBV ( Epstein Barr Virus ) Vaccine ( 268664 ) .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adolescent/adult subject include 16 25 year age time screen . Written inform consent obtain subject prior enrolment . Seronegative EBV antibody . Administration immunoglobulin and/or blood product within three month ( 90 day ) precede first dose study vaccine plan administration study period . Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . Family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . History neurologic disorder seizure , exception single febrile seizure childhood . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . History intravenous drug abuse within past 2 year . Known suspected allergy vaccine component .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Epstein Barr Virus</keyword>
	<keyword>Belgium</keyword>
	<keyword>Infectious mononucleosis</keyword>
</DOC>